EMATOLOGIA

GIUGNO 2026

LYMPHOMAS

Odronextamab più chop in prima linea nel linfoma diffuso a grandi cellule b (dlbcl): risultati della parte 1b dello studio olympia-3

Firme proteomiche periferiche associate alla sindrome da rilascio di citochine (crs) nei pazienti (pts) con linfoma diffuso a grandi cellule b (dlbcl) e linfoma follicolare (fl) trattati con odronextamab

Tassi di infezione nei pazienti (pts) con linfoma non-hodgkin a cellule b (b-nhl): un’analisi real-world

Polatuzumab vedotin più rituximab, ifosfamide, carboplatino ed etoposide (pola-r-ice) versus r-ice come trattamento di seconda linea nel linfoma a grandi cellule b (lbcl): analisi finale di uno studio randomizzato di fase 3

Dati di sicurezza e primi dati aggregati di efficacia dello studio di fase 3 polar bear del nordic lymphoma group in pazienti anziani o fragili con linfoma diffuso a grandi cellule b: r-pola-mini-chp versus r-mini-chop

MM-AMYLOIDOSIS

Dati iniziali di efficacia e sicurezza dello studio linker-al2 di fase 1/2 su linvoseltamab (linvo) in monoterapia in pazienti con amiloidosi sistemica a catene leggere (al) recidivante o refrattaria (rr)

Efficacia comparativa di linvoseltamab rispetto a teclistamab nel mieloma multiplo recidivato/refrattario esposto alle tre classi terapeutiche: aggiornamento dell’analisi indiretta corretta per matching (matching-adjusted indirect comparison) con un follow-up più prolungato

Approccio curativo aggressivo nella gammopatia multipla smoldering mediante valutazione di nuove terapie (ascent): studio di fase 2 di induzione, consolidamento e mantenimento nel mieloma multiplo smoldering ad alto rischio

Disegno dello studio di fase 3 emn39/lumyna linker-mm6: induzione con daratumumab-lenalidomide-desametasone (drd) seguita da linvoseltamab versus drd nei pazienti con mieloma multiplo di nuova diagnosi non eleggibili al trapianto

Esiti nel real world e utilizzo dei trattamenti successivi dopo esposizione ad anticorpi farmaco-coniugati anti-antigene di maturazione delle cellule b (anti-bcma adc) nei pazienti con mieloma multiplo

Esiti nel real world del mieloma multiplo smoldering in europa: primi risultati dello studio spark

CML

Asc4first wk 144 analysis: continued superior efficacy and favorable safety of asciminib vs investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic phase chronic myeloid leukemia

Frontline asciminib for chronic phase cml: long term safety and efficacy in the allg cm13 ascend trial

Emotional distress dominates quality of life burden in cml: psychometric validation of patient reported outcomes in a global leukemia experience survey

Asciminib for newly diagnosed chronic myeloid leukemia: interim results from a phase ii trial

How many chronic-phase cml patients starting tyrosine kinase inhibitors can achieve a persistent treatment free remission and be potentially cured? a single center real-life experience

Asciminib versus second-generation tkis in chronic-phase cml after ≥2 prior tkis: a propensity score-matched analysis

Asciminib in chronic-phase cml after prior tki intolerance or resistance: real-world outcomes from a single-center cohort

Rapid molecular responses and preserved quality of life with asciminib in chronic myeloid leukemia: a real-world study

Efficacy and safety of adding low dose tyrosine kinase inhibitors (tkis) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission (alert cml)

Risk of permanent frontline discontinuation during the first 36 months of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia: a “campus cml” study with a new “ad hoc” score proposal

ITP

Effect of ianalumab plus eltrombopag on patient-reported outcomes in primary immune thrombocytopenia: results from the vayhit2 phase 3 trial

Effects of ianalumab treatment on b cell activation, maturation, and maintenance of vaccine titers in patients with primary immune thrombocytopenia in the phase 2 vayhit3 study

MPN

Evaluation of pelabresib (pela) as add-on therapy to janus kinase inhibitor (jaki) ruxolitinib (rux) in myelofibrosis (mf) patients: results from arm 2 of the open-label, phase 2 manifest study

Pelabresib monotherapy in myelofibrosis after janus kinase inhibitor failure: results from arm 1 of the open-label, phase 2 manifest study

NHL

Tisagenlecleucel in pediatric and young adult patients with high-risk b-cell acute lymphoblastic leukemia and minimal residual disease at the end of frontline consolidation

Pet-integrated nomograms for survival prediction in patients with large b-cell lymphoma treated with car t-cell therapy

International expert consensus on real-world car t-cell eligibility in large b-cell lymphomas: an e-delphi study

Radiotherapy as bridging, salvage or consolidation strategy in car-t–treated lymphoma patients: insights from the french descar-t registry

Nutritional parameters as prognostic markers in older patients with diffuse large b-cell lymphoma: a post-hoc analysis of the elderly project by fondazione italiana linfomi

PNH

Iptacopan demonstrates sustained efficacy and safety in paroxysmal nocturnal hemoglobinuria: up to 4 years of follow-up in patients from apply, appoint and roll-over extension program

Consistent and sustained efficacy and safety of iptacopan in paroxysmal nocturnal hemoglobinuria regardless of prior history of major adverse vascular events in apply, appoint and extension program

Long-term safety with iptacopan treatment in patients with paroxysmal nocturnal hemoglobinuria (pnh): pooled analysis of data from phase 2 and 3 studies and the roll-over extension program

Real-world outcomes of iptacopan in paroxysmal nocturnal hemoglobinuria (pnh) patients: insights from the french early access program

Long-term hematologic control and safety in patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: 6-year follow-up from phase 2 studies and roll-over extension program

Clinical burden of pnh patients with hemoglobin between ≥10 and <12 g/dl: results from a multinational real-world study

DICEMBRE 2025

ALL

Asciminib for relapsed or refractory philadelphia-positive acute lymphoblastic leukemia (ph+ all) and lymphoid blast crisis of chronic myeloid leukemia (lbc-cml) in italy: a campus all real life study

CML

A multinational study to explore patient preferences for chronic myeloid leukaemia treatments

Asciminib for newly diagnosed chronic myeloid leukemia: results from a phase ii trial

Asciminib and pregnancy in cml: preliminary human data and clinical implications from 47 reported outcomes

The humanistic burden of patients with chronic myeloid leukemia (cml) treated with first line (1l) tyrosine kinase inhibitors (tkis)

ITP

Real-world study on thrombopoietin receptor agonists combined with rituximab in the treatment of relapsed/refractory primary immune thrombocytopenia

Clinical and economic burden of steroids in primary immune thrombocytopenia: a real-world italian analysis

MPN

It’s not yet time to abandon ruxolitinib in anemic myelofibrosis: predictive factors of erythroid response to standard anemia-directed therapies combined with ruxolitinib

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in jak inhibitor–naive myelofibrosis: 96-week results from the phase iii manifest-2 study

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: an analysis of the medicare fee-for-service claims database

Dipss-r: a revised age-agnostic clinical risk model for chronic phase primary myelofibrosis

Changes in neutrophil-to-lymphocyte ratio (nlr) in patients with polycythemia vera treated with ruxolitinib reflect changes of jak2 variant allele frequency (vaf)

Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: a real-world analysis of the medicare fee-for-service claims database

NHL

Nhl optimizing fludarabine exposure using pharmacokinetic modeling in pediatric patients receiving tisagenlecleucel: a step toward personalized lymphodepletion

Outcomes in the 2nd decade following follicular lymphoma (fl) diagnosis: long-term follow-up from the university of iowa/mayo clinic spore molecular epidemiology resource (mer)

Are all gelf criteria created equal? utility of individual gelf criteria as guidance for treatment initiation in patients with advanced stage fl

PNH

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

 real-world treatment patterns and clinical outcomes among patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan in the united states

Management of a real-world cohort of patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: a multi-institutional analysis

Navigating the complement cascade: a multicenter journey from pegcetacoplan to iptacopan in paroxysmal nocturnal hemoglobinuria

Real-world data on breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with proximal and terminal complement inhibitors.

Switching between complement inhibitors in patients with pnh: a real-world analysis of strategy, efficacy, and safety

SETTING-TX

An integrative prognostic model for transplant outcomes in myelofibrosis

Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: a prospective multicenter phase ii trial

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the united states: a long-term follow-up analysis

CLL

Pirtobrutinib nella cll/sll post-cbtki: aggiornamento finale dello studio di fase 1/2 bruin con oltre 5 anni di follow-up

Efficacia e sicurezza del pirtobrutinib nei pazienti affetti da cll/sll: studio di fase 2 in corso per l'ottimizzazione del dosaggio

Risultati di pirtobrutinib nella leucemia linfocitica cronica/linfoma linfocitico piccolo (cll/sll) di seconda linea (2l) dopo terapia cbtki di prima linea (1l): un'analisi aggregata degli studi bruin loxo-btk18001 e bruin cll-321

Pirtobrutinib vs ibrutinib nel trattamento della cll/sll naïve e recidivante/refrattaria: risultati del primo studio randomizzato di fase iii che confronta un inibitore btk non covalente e uno covalente

Pirtobrutinib vs bendamustina più rituximab (br) in pazienti con cll/sll: primi risultati di uno studio randomizzato di fase iii esame di un inibitore btk non covalente in pazienti non trattati

Il pirtobrutinib, un inibitore non covalente della btk, potenzia l'immunità antitumorale delle cellule t nella leucemia linfocitica cronica (llc)

Efficacia della monoterapia con pirtobrutinib nella leucemia linfocitica cronica non trattata in precedenza: una meta-analisi bayesiana di studi randomizzati controllati

Impatto dell'uso precedente di venetoclax sulla mortalità nei pazienti affetti da llc trattati con pirtobrutinib: uno studio di coorte con abbinamento per propensione

MCL

Pirtobrutinib nel linfoma mantellare recidivante/refrattario (r/r): aggiornamento finale dello studio di fase 1/2 bruin

GIUGNO 2025

CML

Asciminib (asc) shows superior tolerability vs nilotinib (nil) in newly diagnosed chronic myeloid leukemia in chronic phase (cml-cp): primary endpoint results of the phase (ph) 3b asc4start trial

Improved patient-reported outcomes (pros) with asciminib (asc) vs investigator-selected tyrosine kinase inhibitors (is-tkis) in newly diagnosed chronic myeloid leukemia (cml): asc4first wk 48 analysis

Interim analysis (ia) results from asc2escalate support asciminib (asc) as a treatment (tx) option in chronic-phase chronic myeloid leukemia (cml-cp) after 1 tyrosine kinase inhibitor (tki)

Asc4opt study: high efficacy and favorable tolerability of asciminib once or twice daily in cml patients with suboptimal response, resistance or intolerance of 2 or more tyrosine kinase inhibitors

Exploratory analysis of prevalent additional genomic alterations (agas) at baseline (bl) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (cml-cp) from asc4first

Asciminib after one prior tyrosine kinase inhibitor in patients with chronic myeloid leukemia - a physician panel-based chart review study in the united states

Impact of adverse events on quality of life in chronic myeloid leukemia (cml) - results from the patient survey on humanistic burden of intolerance to first or second tkis (shift) study in the us

New pediatric formulation of asciminib in children with chronic myeloid leukemia in chronic phase: second interim analysis of pharmacokinetics, safety and growth data from the asc4kids study

FL

4-year update of phase 2 elara trial: clinical outcomes of tisagenlecleucel in patients (pts) with high-risk relapsed/refractory follicular lymphoma (r/r fl)

Tisagenlecleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma: an updated matching-adjusted indirect comparison (maic) analysis after 3-year follow-up data

Rapcabtagene autoleucel (ytb323) in patients with relapsed/refractory diffuse large b-cell lymphoma: a phase ii trial clinical update

Pregnancy and infant outcomes post-cd19-directed car-t therapy: tisagenlecleucel (tisa-cel) and/or hucar19 (ctl119)

Three-year real-world mortality analysis of car-t therapies: tisa-cel, axi-cel, and liso-cel

ITP

Ianalumab' s dual mechanism of action: targeting b cells through enhanced b-cell depletion and blockade of b cell-activating factor receptor signaling

Associations between illness perceptions and health-related quality of life in adults with primary immune thrombocytopenia: a cross-sectional greek study

MPN

Impact of eln clinical signs and symptoms on outcomes in polycythemia vera patients treated with hydroxyurea or ruxolitinib: a cooperative study

Retrospective analysis of efficacy and safety outcomes in patients with primary and secondary myelofibrosis treated with ruxolitinib: jump study

Clinical pathways and prognostic strategies in myelofibrosis: a real-world analysis of german practice

Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia supporting medications

Pelabresib in combination with ruxolitinib for janus kinase inhibitor-naive patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase iii manifest-2 study

Health-related quality of life and symptom burden in pre-fibrotic and overt myelofibrosis compared to the general population and physician perceptions: results from the gimema-prophecy study

PNH

Effectiveness and safety of iptacopan in paroxysmal nocturnal hemoglobinuria patients with persistent anemia after c5 inhibition: the real-world experience of the french early access program

The 2-year safety and efficacy of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria (pnh) from apply- and appoint-pnh studies who entered the roll-over extension program (rep)

Appulse-pnh: oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin (hb) increases in patients (pts) with paroxysmal nocturnal hemoglobinuria (pnh) and hb ≥10 g/dl on anti-c5 therapy

Obtaining insights on pnh management with iptacopan in everyday clinical practice: a research collaboration with the ipig pnh registry

DICEMBRE 2024

CML

Prognostic implication of framingham risk score as a comorbidity measure on treatment outcomes following first-line tyrosine kinase inhibitor in newly diagnosed cml patients

Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (cml-cp): interim results from the phase 2 asc2escalate trial in the cohort of patients (pts) after 1 prior tyrosine kinase inhibitor (tki)

Treatment with asciminib as a second line after one prior tyrosine kinase inhibitor (tki) in patients with chronic-phase chronic myeloid leukemia (cml-cp) – a chart review study in the united states

Asciminib provides long-term, durable molecular responses in patients with t315i-mutated cml-cp: final analysis from a phase 1 trial

Retrospective study to compare treatment outcomes of asciminib vs. ponatinib in 99 patients with t315i mutated chronic myeloid leukemia

Molecular outcome of chronic myeloid leukemia affected patients not in deep molecular response: the “others” from the gimema labnet network

Tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia: observational study of 673 patients in italy

Increased inflammatory cytokines in plasma are associated with sustained treatment-free remission in chronic myeloid leukaemia

FL

Outcome of hematopoietic stem cell transplantation for follicular lymphoma, a benchmark study from the lymphoma working party of the european society for blood and marrow transplantation

Impact of minimal residual disease analysis in the era of rituximab maintenance in follicular lymphoma: data from "foll12" phase iii trial of the fondazione italiana linfomi

Clinical outcomes of transformed follicular lymphoma with car t-cell therapy: a us multicenter real-world analysis

Efficacy and safety of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma: a real-world analysis from the center for blood and marrow transplant research (cibmtr) registry

Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 4-year update

GVHD

A multicenter randomized controlled trial of low-dose ruxolitinib for gvhd prophylaxis in haploidentical hematopoietic stem cell transplantation

Early safety and feasibility results from a phase ii trial of de-escalated ptcy and ruxolitinib for gvhd prophylaxis in older patients undergoing reduced intensity conditioning allogeneic hct

Prevalence and outcomes of opportunistic infections in steroid refractory graft versus host disease patients treated with ruxolitinib, ibrutinib, and belumosudil

ITP

Efficacy findings in a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children

Ianalumab, an adcc-enhanced anti-baff-receptor antibody, has beneficial effects in an active mouse model of immune thrombocytopenia (itp)

MPN

Prognostic insights on pre-fibrotic primary myelofibrosis: a clinical-pathological perspective in 762 patients

Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with ruxolitinib in participants with myelofibrosis from the ongoing phase 2 restore trial

Multicenter, open-label phase 1/2a study of pxs-5505 and ruxolitinib in patients with primary, post-polycythemia vera (pv) or post-essential thrombocythemia (et) myelofibrosis

The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated myelofibrosis patients: the interim analysis of a prospective, open-label, multicenter, parallel-cohort, phase 2 study

Trial update from improvemf, an ongoing, open-label, dose-escalation and -expansion, phase 1/1b trial to evaluate the safety, pharmacokinetics, and clinical activity of the novel combination of imetelstat with ruxolitinib in patients with intermediate-1, intermediate-2, or high-risk myelofibrosis (mf)

Interim analysis of promise, a clinical study combining the bet inhibitor opn-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib

Bomedemstat (mk3543) in combination with ruxolitinib in patients with advanced myelofibrosis

Revised international working group risk model for survival in polycythemia vera

Outcomes of allogeneic hematopoietic stem cell transplantation in older patients aged over 70 years with myelofibrosis

Myelofibrosis therapies and risk of major bleeding, thrombotic events and mortality, a matched nationwide population-based study

PNH

Incremental effectiveness of iptacopan compared with c5 inhibitors in adult patients with paroxysmal nocturnal hemoglobinuria: results from a modelling analysis

GIUGNO 2024

CML

Propensity score matching analysis comparing asciminib versus ponatinib for its treatment outomes in chronic myeloid leukemia patients

Asc4real: efficacy and tolerability comparison between ascembl study, a phase 3 randomized clinical trial (rct), and real- world (rw) experience with asciminib in cml patients beyond 2 tkis

Results of therapy of asciminib and ponatinib in chronic myeloid leukemia patients with failure to more than 2 tyrosine kinase inhibitors and / or bcr::abl1 t315i mutation

Deep molecular response rate in chronic phase chronic myeloid leukemia. eligibility to discontinuation related to time to response and different frontline tki: the labnet cml national network

Second tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia-chronic phase patients: single center real-life experience

Interaction between gut microbiome and tyrosine kinase inhibitors in defining the clinical outcomes of patients with chronic myeloid leukemia

FL

Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 3-year follow-up

Long-term durable responses in patients with r/r all, dlbcl, and fl treated with tisagenlecleucel and its association with persistence of chimeric antigen receptor (car) t-cells

Comparable outcomes of cd19-targeting car-t therapy in transformed follicular lymphoma and de novo diffuse large bcell lymphoma”

Treatment preferences and quality of life in patients with relapsed / refractory follicular lymphoma

Frequency of car-t cell manufacturing failures and out-of specification products in the real-world setting: a survey from the ebmt cellular therapy and immunobiology working party (ctiwp)

GVHD

Comparison of incidence and clinical characteristics of graft versus host disease among recipients of allogeneic stem cell transplantation from identical vs haploidentical donors in colombia

New marker and target: tsrna marks the activation of t cells providing early detection and therapy of gvhd after allogeneic stem cell transplantation

ITP-PNH

Eltrombopag inhibits the proliferation of cd8 t cells through an iron chelation manner

Prolonged response after tpo-ra discontinuation in primary itp: long term follow-up of the stopago study, a prospective multicenter study

Clonal hematopoiesis in patients with immune thrombocytopenia: an international multicenter study

MPN

The impact of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib: results from the expanded-access jump study

Intermediate-1 risk myelofibrosis patients treated with ruxolitinib: predictors of response and outcome may drive transplant decision

Real-world efficacy and safety of ruxolitinib in the treatment of elderly myelofibrosis patients: a retrospective study